Abstract
The aim of this investigation is to evaluate the presence of Gram-negative isolates with resistance to ceftazidime-avibactam, a new antimicrobial introduced on the Brazilian market in 2018, in clinical isolates from patients with healthcare-associated infections. To this end, 100 isolates received at our reference laboratory (Center for Bacteriology, Adolfo Lutz Institute) will be evaluat…